-
Je něco špatně v tomto záznamu ?
Pulmonary perfusion in long-term survivors of COVID-19-related severe acute respiratory distress syndrome treated by extracorporeal membrane oxygenation
L. Miksová, V. Dytrych, V. Ptáčník, M. Balík, A. Linhart, J. Bělohlávek, P. Jansa
Status neindexováno Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2017
PubMed Central
od 2011
Europe PubMed Central
od 2011
ProQuest Central
od 2011-01-01
Health & Medicine (ProQuest)
od 2011-01-01
Wiley-Blackwell Open Access Titles
od 2011
PubMed
39188535
DOI
10.1002/pul2.12431
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
COVID-19 associates with a hypercoagulant state and an increased risk for venous thromboembolic events (VTEs). Whether severe COVID-19 infection requiring extracorporeal membrane oxygenation (ECMO) support might lead to chronic pulmonary perfusion abnormalities and chronic thromboembolic pulmonary disease/hypertension remains unclear. The purpose of this study was to evaluate chronic pulmonary perfusion abnormalities in long-term survivors of COVID-19-related severe acute respiratory distress syndrome (ARDS) treated by ECMO at our institution. Pulmonary perfusion was examined by ventilation/perfusion (V/Q) single-photon emission computed tomography or V/Q planar scintigraphy at least 3 months after ECMO explantation, comorbidities and incidence of thromboembolic events were recorded as well. Of 172 COVID-19 patients treated by ECMO for severe COVID-19 pneumonia between March 2020 and November 2021, only 80 were successfully weaned from ECMO. Of those, 37 patients were enrolled into the present analysis (27% female, mean age 52 years). Median duration of ECMO support was 12 days. In 24 (65%) patients VTE was recorded in the acute phase (23 patients developed ECMO cannula-related deep vein thrombosis, 5 of them had also a pulmonary embolism, and one thrombus was associated with a central catheter). The median duration between ECMO explantation and assessment of pulmonary perfusion was 420 days. No segmental or larger mismatched perfusion defects were then detected in any patient. In conclusion, in long-term survivors of COVID-19-related ARDS treated by ECMO, no persistent pulmonary perfusion abnormalities were detected although VTE was common.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24017971
- 003
- CZ-PrNML
- 005
- 20241016082006.0
- 007
- ta
- 008
- 241008s2024 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/pul2.12431 $2 doi
- 035 __
- $a (PubMed)39188535
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Miksová, Lucie $u Clinical Department of Cardiology and Angiology of the 2nd Department of Medicine General University Hospital in Prague Prague Czech Republic $1 https://orcid.org/0009000750432281
- 245 10
- $a Pulmonary perfusion in long-term survivors of COVID-19-related severe acute respiratory distress syndrome treated by extracorporeal membrane oxygenation / $c L. Miksová, V. Dytrych, V. Ptáčník, M. Balík, A. Linhart, J. Bělohlávek, P. Jansa
- 520 9_
- $a COVID-19 associates with a hypercoagulant state and an increased risk for venous thromboembolic events (VTEs). Whether severe COVID-19 infection requiring extracorporeal membrane oxygenation (ECMO) support might lead to chronic pulmonary perfusion abnormalities and chronic thromboembolic pulmonary disease/hypertension remains unclear. The purpose of this study was to evaluate chronic pulmonary perfusion abnormalities in long-term survivors of COVID-19-related severe acute respiratory distress syndrome (ARDS) treated by ECMO at our institution. Pulmonary perfusion was examined by ventilation/perfusion (V/Q) single-photon emission computed tomography or V/Q planar scintigraphy at least 3 months after ECMO explantation, comorbidities and incidence of thromboembolic events were recorded as well. Of 172 COVID-19 patients treated by ECMO for severe COVID-19 pneumonia between March 2020 and November 2021, only 80 were successfully weaned from ECMO. Of those, 37 patients were enrolled into the present analysis (27% female, mean age 52 years). Median duration of ECMO support was 12 days. In 24 (65%) patients VTE was recorded in the acute phase (23 patients developed ECMO cannula-related deep vein thrombosis, 5 of them had also a pulmonary embolism, and one thrombus was associated with a central catheter). The median duration between ECMO explantation and assessment of pulmonary perfusion was 420 days. No segmental or larger mismatched perfusion defects were then detected in any patient. In conclusion, in long-term survivors of COVID-19-related ARDS treated by ECMO, no persistent pulmonary perfusion abnormalities were detected although VTE was common.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Dytrych, Vladimír $u Clinical Department of Cardiology and Angiology of the 2nd Department of Medicine General University Hospital in Prague Prague Czech Republic
- 700 1_
- $a Ptáčník, Václav $u Institute of Nuclear Medicine of the 1st Faculty of Medicine and General University Hospital in Prague Prague Czech Republic
- 700 1_
- $a Balík, Martin $u Department of Anesthesiology and Intensive Care of the 1st Faculty of Medicine and General University Hospital in Prague Prague Czech Republic $1 https://orcid.org/0000000318642143 $7 xx0075661
- 700 1_
- $a Linhart, Aleš $u Clinical Department of Cardiology and Angiology of the 2nd Department of Medicine General University Hospital in Prague Prague Czech Republic
- 700 1_
- $a Bělohlávek, Jan $u Clinical Department of Cardiology and Angiology of the 2nd Department of Medicine General University Hospital in Prague Prague Czech Republic
- 700 1_
- $a Jansa, Pavel $u Clinical Department of Cardiology and Angiology of the 2nd Department of Medicine General University Hospital in Prague Prague Czech Republic
- 773 0_
- $w MED00200184 $t Pulmonary circulation $x 2045-8932 $g Roč. 14, č. 3 (2024), s. e12431
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39188535 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241008 $b ABA008
- 991 __
- $a 20241016082001 $b ABA008
- 999 __
- $a ok $b bmc $g 2196423 $s 1229922
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2024 $b 14 $c 3 $d e12431 $e 20240825 $i 2045-8932 $m Pulmonary circulation $n Pulm Circ $x MED00200184
- LZP __
- $a Pubmed-20241008